Adial Pharmaceuticals, Inc (ADIL) financial statements (2021 and earlier)

Company profile

Business Address 1180 SEMINOLE TRAIL
CHARLOTTESVILLE, VA 22901
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments4,4017,3658,6244,9526,7778,53010,254
Cash and cash equivalents4,4017,3658,6244,9526,7778,53010,254
Prepaid expense233214669743831460272
Intangible current assets1   1  
Other undisclosed current assets50159317724064511155
Total current assets:5,1368,1729,4695,9357,6739,50110,681
Noncurrent Assets
Intangible assets, net (including goodwill)6      
Intangible assets, net (excluding goodwill)6      
Other noncurrent assets 666666
Other undisclosed noncurrent assets350      
Total noncurrent assets:356666666
TOTAL ASSETS:5,4918,1789,4755,9417,6809,50710,687
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:1,5051,093682196539777627
Accounts payable649247442 190475 
Accrued liabilities85784624019334930 
Employee-related liabilities   112   
Other undisclosed accounts payable and accrued liabilities   (109) 272627
Other undisclosed current liabilities   193   
Total current liabilities:1,5051,093682390539777627
Noncurrent Liabilities
Total liabilities:1,5051,093682390539777627
Stockholders' equity
Stockholders' equity attributable to parent3,9867,0858,7935,5517,1418,73010,061
Common stock14141311101010
Additional paid in capital35,49135,12133,49428,44427,75727,28826,903
Accumulated deficit(31,520)(28,051)(24,715)(22,904)(20,627)(18,568)(16,852)
Total stockholders' equity:3,9867,0858,7935,5517,1418,73010,061
TOTAL LIABILITIES AND EQUITY:5,4918,1789,4755,9417,6809,50710,687

Income statement (P&L) ($ in thousands)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Revenues376      
Operating expenses(3,471)(3,338)(1,819)(2,300)(2,091)(1,746)(2,159)
Operating loss:(3,471)(3,338)(1,819)(2,300)(2,091)(1,746)(2,159)
Nonoperating income13823323025
Investment income, nonoperating13523323025
Other nonoperating income  3    
Loss from continuing operations before income taxes:(3,469)(3,336)(1,811)(2,277)(2,058)(1,716)(2,134)
Other undisclosed income (loss) from continuing operations446   (14,246)  
Loss before gain (loss) on sale of properties:(3,023)(3,336)(1,811)(2,277)(16,305)(1,716)(2,134)
Other undisclosed net income (loss)(446)   14,246  
Net loss available to common stockholders, diluted:(3,469)(3,336)(1,811)(2,277)(2,058)(1,716)(2,134)

Comprehensive Income ($ in thousands)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Net loss:(3,469)(3,336)(1,811)(2,277)(2,058)(1,716)(2,134)
Comprehensive loss, net of tax, attributable to parent:(3,469)(3,336)(1,811)(2,277)(2,058)(1,716)(2,134)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: